Emcure Pharmaceuticals Faces ₹57.74 Crore Penalty from Income-Tax Department
Emcure Pharmaceuticals received penalty orders totaling ₹57.74 crore from the Income-tax Department for FY15-FY21. The company is evaluating legal remedies and plans to file an appeal against the orders.
A penalty of ₹57.74 crore can have a moderate impact on the company's financials and profitability, pending the outcome of the appeal.
The company has been penalized by the Income-tax Department, which is a negative financial event.
Emcure Pharmaceuticals Limited has received orders from the Income-tax Department imposing an aggregate penalty of ₹57,73,96,732 for the financial years 2014-15 to 2020-21 (Assessment Years 2015-16 to 2021-22).
The company disclosed this information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This matter pertains to ongoing litigations that were previously disclosed in the Integrated Governance Reports, with the latest report being for the quarter ended June 30, 2026.
Emcure Pharmaceuticals is currently evaluating its legal options and plans to file an appeal before the Appellate Authority. The opposing party in this litigation is the Deputy Commissioner of Income-tax, Central Circle 2 (1) - Pune. The litigation was initiated on December 27, 2023.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.